Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Malignant Acanthosis Nigricans as a Sign of Gastrointestinal Cancer

Description

The speaker presents a case of malignant acanthosis nigricans in a 59-year-old man with a worsening, itchy rash affecting multiple body areas, including the mouth and groin, along with systemic symptoms such as diarrhea, joint pain, abdominal pain, and feeling unwell. The key teaching point is that malignant acanthosis nigricans is most commonly associated with gastrointestinal malignancy, often appearing around the time the cancer is diagnosed, though it can also occur before or after. In this patient, the rash was linked to known metastatic gastroesophageal junction cancer, not to the newly started immunotherapy nivolumab, so treatment should not be stopped for that reason. The talk reviews that acanthosis nigricans is usually a clinical diagnosis characterized by skin thickening rather than true pigmentation, contrasts malignant causes with the far more common insulin-resistance form, and explains that management focuses on treating the underlying condition. The speaker also mentions emerging reports suggesting EGFR inhibitors may improve some malignant cases and highlights the importance of recognizing the condition as a potential sign of internal cancer.

View more

Conclusions

  • Malignant acanthosis nigricans is a rare paraneoplastic skin finding that is most often linked to gastrointestinal cancers.
  • In most cases, acanthosis nigricans appears around the time the cancer is diagnosed, though it can occur before or after diagnosis.
  • The skin changes are driven by the underlying disease process rather than by immunotherapy or other cancer treatment initiation.
  • Acanthosis nigricans is primarily a clinical diagnosis and does not usually require biopsy when the presentation is typical.
  • Management should focus on treating the underlying cause, especially the malignancy or other systemic driver, rather than on topical skin-directed therapy alone.
  • Malignancy-associated acanthosis nigricans may be mediated by growth-factor signaling, particularly EGFR-related pathways, which may offer a future therapeutic target in selected cases.
  • Chu HW, Li JM, Chen GF, Ma JY. Oral malignant acanthosis nigricans associated with endometrial adenocarcinoma. Int J Oral Sci. 2014 Dec;6(4):247-9.#10.1038/ijos.2014.1
  • Wei-Ti Chen and Chia-Hui Chu. Tripe palm: a paraneoplastic manifestation of gastric cancer. CMAJ April 01, 2019 191(13) E366; DOI: 10.1503/cmaj.181104.#10.1503/cmaj.181104
  • Cutaneous paraneoplastic syndromes, Seminars in Diagnostic Pathology, Vol 36, Issue 4, 2019, Pages 211-228.#10.1053/j.semdp.2019.01.001
  • Genes, growth factors and acanthosis nigricans, British Journal of Dermatology, Volume 147, Issue 6, 1 December 2002, Pages 1096–1101.#10.1046/j.1365-2133.2002.05150.x